Viridian Therapeutics, Inc.\DE (VRDN) · Nov 4, 2026 · Earnings
Beat — Net revenue $25.8M vs ~$4.7M consensus; EPS loss $0.81 vs ~$1.02 expected
Viridian earnings show Lumvoa’s launch is ahead of expectations, while cash and pipeline milestones support the next growth phase.
Viridian is moving from biotech development into its first commercial phase: Lumvoa was approved for thyroid eye disease in June 2026, while elegrobart remains the next major TED product and the company is expanding into TSHR and FcRn programs.
The launch materially outperformed the available revenue bar. Lumvoa generated $24.7 million of product revenue in its first reported commercial quarter, versus published expectations around $4.7 million; total revenue reached $25.8 million, while the consensus EPS loss was about $1.02 and the company reported a $0.81 loss per share. That is a genuine earnings beat, not merely a favorable comparison with a zero-revenue prior-year quarter.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Product revenue (Financial Results) | $24.7M | $0 | ~$4.7M |
| Total revenue (Income Statement) | $25.8M | $70.6M | — |
| Net loss/share (Income Statement) | $(0.81) | $(0.34) | $(1.02) |
| R&D expense (Income Statement) | $70.1M | $86.3M | — |
| SG&A expense (Income Statement) | $57.6M | $24.3M | — |
| Cash and securities (Balance Sheet) | $955.2M | $874.7M* | — |
*December 31, 2025 comparison.
The beat comes with a deliberate commercial-cost step-up. SG&A more than doubled as Viridian built sales, medical, market-access and patient-support capabilities, and the net loss widened to $101.2 million despite the new revenue. That spending is consistent with a launch-stage company, but it means early revenue growth has not yet translated into operating leverage.
The balance sheet and development timetable remain supportive rather than surprising. Viridian ended September with $955.2 million in cash, cash equivalents and marketable securities, and reiterated the planned Q1 2027 elegrobart BLA. The filing also keeps VRDN-008 data and the VRDN-292 patient trial on track for Q4 2026, so the quarter strengthens the commercial foundation without changing the broader pipeline timetable. 〔0〕
Bottom line: This is a clearly better-than-expected first commercial quarter, led by Lumvoa demand well above the published revenue bar. The larger launch infrastructure bill keeps losses high, but the event advances Viridian’s transition to a revenue-generating company rather than merely confirming the prior story.
VRDN-008 data and VRDN-292 phase 1 initiation, Q4 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!